(SE) The most common pulse sequence used in MR imaging is based of the detection of a spin or Hahn echo. It uses 90° radio frequency pulses to excite the magnetization and one or more 180° pulses to refocus the spins to generate signal echoes named spin echoes (SE).
In the pulse sequence timing diagram, the simplest form of a spin echo sequence is illustrated.
The 90° excitation pulse rotates the longitudinal magnetization (Mz) into the xy-plane and the dephasing of the transverse magnetization (Mxy) starts.
The following application of a 180° refocusing pulse (rotates the magnetization in the x-plane) generates signal echoes. The purpose of the 180° pulse is to rephase the spins, causing them to regain coherence and thereby to recover transverse magnetization, producing a spin echo.
The recovery of the z-magnetization occurs with the T1 relaxation time and typically at a much slower rate than the T2-decay, because in general T1 is greater than T2 for living tissues and is in the range of 100-2000 ms.
The SE pulse sequence was devised in the early days of NMR days by Carr and Purcell and exists now in many forms: the multi echo pulse sequence using single or multislice acquisition, the fast spin echo (FSE/TSE) pulse sequence, echo planar imaging (EPI) pulse sequence and the gradient and spin echo (GRASE) pulse sequence;; all are basically spin echo sequences.
In the simplest form of SE imaging, the pulse sequence has to be repeated as many times as the image has lines.
Contrast values:
PD weighted: Short TE (20 ms) and long TR.
T1 weighted: Short TE (10-20 ms) and short TR (300-600 ms)
T2 weighted: Long TE (greater than 60 ms) and long TR (greater than 1600 ms)
With spin echo imaging no T2* occurs, caused by the 180° refocusing pulse. For this reason, spin echo sequences are more robust against e.g., susceptibility artifacts than gradient echo sequences.

See also Pulse Sequence Timing Diagram to find a description of the components.

A form of a spin echo produced by three pulse RF sequences, consisting of two RF pulses following an initial exciting RF pulse. The stimulated echo appears at a time delay after the third pulse equal to the interval between the first two pulses. Although classically produced with 90° pulses, any RF pulses other than an ideal 180° can produce a stimulated echo. The intensity of the echo depends in part on the T1 relaxation time because the excitation is 'stored' as longitudinal magnetization between the second and third RF pulses. For example, use of stimulated echoes with spatially selective excitation with orthogonal magnetic field gradients permits volume-selective excitation for spectroscopic localization.

Artifacts may appear as a series of fine lines. A narrow bandwidth causes a wide read window, which allows the stimulated echo to be incorporated into the image data. This can be supported by increasing the received bandwidth, which would narrow the read window, thus not incorporating the extraneous echo. Another help would be to change the first echo time, which may change the spacing of the stimulated echoes to outside that of the read window for the second echo.

Small particles of ferrite are used as superparamagnetic contrast medium in MR imaging (appearing predominantly dark on MRI). These agents exhibit strong T1 relaxation properties, and due to susceptibility differences to their surroundings also produce a strongly varying local magnetic field, which enhances T2 relaxation to darken the contrast media containing structures.
Superparamagnetic contrast agents are also known by the abbreviation SPIO's (small particle iron oxide or superparamagnetic iron oxide) and USPIO's (ultrasmall particle iron oxide or ultrasmall superparamagnetic iron oxide).
Two types of USPIO will be available on the market as blood pool agents, while SPIO's have been used as darkening contrast agents for liver imaging. As particulate matter they are taken up by the RES. Very small particles of less than 300 nanometers also remain intravascular for a prolonged period of time and thus can serve as blood pool agents.

See also the related poll result: 'The development of contrast agents in MRI is'

(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.